$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.